Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Xulei Huo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Chordoma, Skull Base Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Skull base chordoma is a rare and aggressive tumour of the bone that has a high likelihood of recurrence. The fundamental differences in single cells between primary and recurrent lesions remain poorly understood, impeding development of effective treatment approaches.
Methods
To obtain an understanding of the differences in single cells between primary and recurrent chordomas, we performed single‐cell RNA sequencing and T‐cell/B‐cell receptor (BCR) sequencing. This allowed us to delineate the differences between the two types of tumour cells, tumour‐infiltrating lymphocytes, myeloid cells, fibroblasts and B cells. Copy number variants (CNVs) were detected and compared between the tumour types to assess heterogeneity. Selected samples were subjected to immunohistochemistry to validate protein expression. Fluorescence in situ hybridisation experiments, Transwell assays and xenograft mouse models helped verify the role of fibronectin 1 (FN1) in chordoma.
Results
Promoting natural killer (NK) cell and CD8_GZMK T‐cell function or inhibiting the transformation of CD8_GZMK T cells to CD8_ZNF683 T cells and promoting the transformation of natural killer T (NKT) cells to NK cells are promising strategies for preventing chordoma recurrence. Additionally, inhibiting the M2‐like activity of tumour‐associated macrophages (TAMs) could be an effective approach. Antigen‐presenting cancer‐associated fibroblasts (apCAFs) and dendritic cells (DCs) with high enrichment of the antigen‐presenting signature were enriched in primary chordomas. There were fewer plasma cells and BCR clonotypes in recurrent chordomas. Remarkably, FN1 was upregulated, had more CNVs, and was more highly secreted by tumours, macrophages, CD4 T cells, CD8 T cells and fibroblasts in recurrent chordoma than in primary chordoma. Finally, FN1 enhanced the invasion and proliferation of chordomas in vivo and in vitro.
Conclusion
Our comprehensive picture of the microenvironment of primary and recurrent chordomas provides deep insights into the mechanisms of chordoma recurrence. FN1 is an important target for chordoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Ke Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huo, X., Ma, S., Wang, C., Song, L., Yao, B., Zhu, S., Li, P., Wang, L., Wu, Z., & Wang, K. (2023). Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1429
Vancouver
Huo X, Ma S, Wang C, Song L, Yao B, Zhu S, et al. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1429
BibTeX
@article{Huo2023,
author = {Huo, Xulei and Ma, Sihan and Wang, Can and Song, Lairong and Yao, Bohan and Zhu, Sipeng and Li, Peiran and Wang, Liang and Wu, Zhen and Wang, Ke},
title = {Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1429}
}
EUVIMED